Copertura documentale

Il Quality Gate pubblico registra 15 supporti documentali, 3 fonti indipendenti e 7 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. — PubMed / NCBI
• Unveiling the Research Landscape of Triazole-based Aromatase Inhibitors in Breast Cancer: Bibliometric Insights — Crossref
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial — ClinicalTrials.gov
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — ClinicalTrials.gov
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) — ClinicalTrials.gov
• Study of 18F-FFNP Breast PET/MRI — ClinicalTrials.gov
• Control of breast cancer via anastrozole-loaded transbilosomes — Crossref
• Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer — ClinicalTrials.gov
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer — ClinicalTrials.gov
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — ClinicalTrials.gov
• Synchronous Triple Malignancy Presentation of Multiple Myeloma and Prefibrotic Primary Myelofibrosis in a Patient With Mucinous Breast Carcinoma: A Case Report From Rural South Africa — Crossref
• PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer — ClinicalTrials.gov

Collegamenti nel Knowledge Graph

• Study of 18F-FFNP Breast PET/MRI — uses intervention
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer — uses intervention
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — uses intervention
• PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer — uses intervention
• Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) — uses intervention
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — uses intervention
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 93/100 · ultimo aggiornamento Settembre 30, 2026